Skip to main content
Jamjoom Pharmaceuticals Factory Co. logo

Jamjoom Pharmaceuticals Factory Co. — Investor Relations & Filings

Ticker · 4015 ISIN · SA15QGU1UNH6 Saudi Exchange Manufacturing
Open in API
Filings indexed 63 across all filing types
Latest filing 2026-05-20 Proxy Solicitation & In…
Country SA Saudi Arabia
Listing Saudi Exchange 4015

About Jamjoom Pharmaceuticals Factory Co.

http://https://www.jamjoompharma.com

Jamjoom Pharmaceuticals Factory Co. is a prominent pharmaceutical manufacturer specializing in the development, production, and distribution of a wide range of generic healthcare products. The company focuses on several key therapeutic areas, including ophthalmology, dermatology, cardiovascular health, and gastrointestinal medicine. It operates advanced manufacturing facilities that adhere to international quality standards, ensuring the delivery of effective and affordable medications. With a significant presence across the Middle East, North Africa, and Central Asia, the organization leverages its research and development capabilities to expand its product portfolio and address diverse medical needs. Its commitment to innovation and quality has established it as a leader in specialized segments, particularly in the ophthalmic market, where it provides a comprehensive suite of treatments.

Recent filings

Filing Released Lang Actions
Jamjoom Pharmaceuticals Factory Co. Board invites its shareholders to attend the Extraordinary General Assembly Meeting (First Meeting) via modern technology means
Proxy Solicitation & Information Statement Classification · 88% confidence The document is an official announcement inviting shareholders to an Extraordinary General Assembly meeting, including meeting details, agenda references, proxy form link, and voting instructions. It provides materials for shareholders to request votes and participate in the meeting, fitting the definition of a proxy solicitation/information statement.
2026-05-20 English
Jamjoom Pharmaceuticals Factory Co. Announces providing a corporate guarantee to its Joint Venture in Algeria
Capital/Financing Update Classification · 85% confidence The document is an issuer announcement on a corporate guarantee and loan facilities provided by Jamjoom Pharmaceuticals to its JV in Algeria. It details the terms and amounts of the new financing facilities and the guarantees backing them. This is not a full financial report, dividend notice, or share issuance—rather, it is an update on the company’s financing arrangements. Therefore, it falls under Capital/Financing Update (CAP).
2026-05-11 English
Jamjoom Pharmaceuticals Factory Co. announces its Interim Financial results for the Period Ending on 2026-03-31 ( Three Months )
Earnings Release Classification · 91% confidence The document is an announcement of Jamjoom Pharmaceuticals’ interim (three-month) financial results with summary tables of revenue, profit, per-share metrics, commentary on year-over-year and quarter-over-quarter changes, and reference to an attached Earnings Release PDF. It is not the full interim report itself but rather the initial quarterly results announcement (key highlights only). This matches the definition of an Earnings Release (ER). Q1 2026
2026-04-23 English
Jamjoom Pharmaceuticals Factory Co. announces the board of director’s decision to distribute cash dividends for Second half of 2025 (Six months)
Notice of Dividend Amount Classification · 100% confidence The document is an announcement from Jamjoom Pharmaceuticals Factory Co. regarding the board of directors' decision to distribute cash dividends for the second half of 2025. It includes specific details such as the dividend amount per share, total amount distributed, eligibility date, and distribution date. The document is short (2785 characters) and focuses solely on dividend distribution details without containing financial statements or comprehensive financial analysis. This matches the definition of a Notice of Dividend Amount (DIV) filing, which announces dividend amounts and payment details to shareholders.
2026-02-24 English
Jamjoom Pharmaceuticals Factory Co. announces its Annual Financial results for the period ending on 31-12-2025
Earnings Release Classification · 95% confidence The document is an announcement of Jamjoom Pharmaceuticals Factory Co.'s annual financial results for the fiscal year ending 31-12-2025. It includes key financial figures such as sales, profit, equity, and explanations for changes compared to the previous year. The document also mentions the external auditor's report with an unmodified opinion and provides additional financial position details. The length of the document is 4428 characters, which is relatively short and includes a link to attached PDF documents. The text primarily serves as a summary announcement of the annual financial results rather than the full detailed annual report itself. According to the 'Menu vs Meal' rule, since the document is short and references attached reports, it should be classified as an Earnings Release (ER) rather than a full Annual Report (10-K). The content focuses on key highlights and financial results, typical of an Earnings Release.
2026-02-24 English
Jamjoom Pharmaceuticals Factory Co. Announces providing a corporate guarantee to its Joint Venture in Algeria
Capital/Financing Update Classification · 95% confidence The document is an announcement by Jamjoom Pharmaceuticals Factory Co. about providing a corporate guarantee to its joint venture in Algeria. It details the signing of a Standby Letter of Credit and the guarantee amount, along with related party disclosures. The content focuses on a financing-related update rather than a full financial report or regulatory filing. The document length is short (2608 characters) and it is an announcement of a specific financing action (corporate guarantee) rather than a report or detailed financial statement. Therefore, it fits best under Capital/Financing Update (CAP).
2026-01-18 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.